Short Interest Runner: ANTRIABIO INCORPORATED (OTCMKTS:ANTB)’s Stock Is Buy After Less Market Selling

November 24, 2016 - By Louis Casey   ·   0 Comments

Short Interest Runner: ANTRIABIO INCORPORATED (OTCMKTS:ANTB)'s Stock Is Buy After Less Market Selling

The stock of ANTRIABIO INCORPORATED (OTCMKTS:ANTB) registered a decrease of 3.49% in short interest. ANTB’s total short interest was 265,100 shares in November as published by FINRA. Its down 3.49% from 274,700 shares, reported previously. With 18,700 shares average volume, it will take short sellers 14 days to cover their ANTB’s short positions. The stock closed at $1.4 during the last session. It is down 35.92% since April 22, 2016 and is uptrending. It has outperformed by 30.51% the S&P500.

AntriaBio, Inc. is a biopharmaceutical company. The company has a market cap of $57.33 million. The Firm develops sustained release injectable therapies. It currently has negative earnings. The Company’s products include AB101 and AB301.

ANTB Company Profile

AntriaBio, Inc., incorporated on January 2, 2013, is a biopharmaceutical company. The Firm develops sustained release injectable therapies. The Company’s products include AB101 and AB301.

More notable recent AntriaBio Inc (OTCMKTS:ANTB) news were published by: Streetinsider.com which released: “Form 8-K AntriaBio, Inc. For: Jun 06” on June 08, 2015, also Seekingalpha.com with their article: “AntriaBio Presents Vast Upside With Disruptive Once-Weekly Insulin” published on July 16, 2014, Marketwatch.com published: “AntriaBio Announces $12 Million Private Placement” on June 29, 2016. More interesting news about AntriaBio Inc (OTCMKTS:ANTB) were released by: Seekingalpha.com and their article: “Preclinical Data At ADA Supports Development Of AntriaBio’s AB101 (ANTB)” published on June 11, 2015 as well as Bizjournals.com‘s news article titled: “As potential once-a-week insulin advances, AntriaBio eliminates a $44M obligation” with publication date: November 11, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>